Myeloid Cell Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035

The market for therapeutics targeting myeloid cells is currently valued at $0.65 billion in 2022 and is projected to grow at a remarkable CAGR of over 40% during the forecast period.

In 2020, there were over 19 million new cancer cases reported, with approximately 10 million cancer-related deaths, indicating a rapid increase in the global cancer burden. In response to this growing prevalence, researchers have made substantial efforts to explore innovative approaches for the treatment of oncological diseases. Among the various programs that have advanced to clinical stages, myeloid cell targeting therapeutics have emerged as a novel strategy within the realm of cancer immunotherapy.

Myeloid cells encompass a group of cells comprising granulocytes, monocytes, macrophages, mast cells, and dendritic cells, all of which play a crucial role in innate immunity. These cells are found abundantly in the tumor microenvironment and inflamed regions. Tumors recruit and manipulate endogenous myeloid cells, transforming them into tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells, and neutrophils to sustain an immunosuppressive environment. Several research studies have demonstrated that myeloid cells can interact with the immune system to generate an effective anti-tumor immune response. Targeting these cells can help modulate cancer-associated activities, including immune evasion. Therefore, myeloid therapies have garnered significant attention as potential complements to existing treatments, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation, aiming to enhance therapeutic responses. Moreover, myeloid cell targeting therapies are under investigation for their potential in the treatment of various inflammatory disorders.

At present, numerous medical researchers and industry stakeholders are actively involved in developing therapeutics that target myeloid cells to harness the immune system for treating various solid tumors, leukemias, and even rare conditions like myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from ongoing studies and completed trials indicate that targeting myeloid cells leads to delayed tumor progression, ultimately improving patient survival rates. This encouraging progress has attracted significant attention from private and public investors, who have collectively invested around USD 4.9 billion in recent years. Fueled by increasing research and development activities, promising clinical data, and financial support from investors, the market for myeloid cell targeting therapeutics is poised to experience substantial growth during the forecast period.

Key Market Segments
Type of Molecule

  • Small Molecule
  • Biologics


Therapeutic Area

  • Oncological Disorders
  • Rare Disorders


Route of Administration

  • Intravenous
  • Oral


Geographical Regions

  • North America
  • Europe
  • Asia Pacific


Research Coverage:

  • The report studies the myeloid cell targeting therapeutics market by type of molecule, therapeutic area, route of administration and geography.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to major regions.
  • An overview of key findings from our research on the myeloid cell targeting therapeutics market, offering insights into its current state and likely evolution in the short, mid, and long term.
  • A comprehensive evaluation of the current market landscape for myeloid cell-targeting therapeutics, considering key parameters like development phase (clinical and preclinical), molecule type (small molecules and biologics), target indications, therapeutic areas (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders, and others), biological targets, administration routes (intravenous, oral, subcutaneous, intra-tumoral, nasal, and others), therapy types (monotherapy and combination therapy), combination drugs, treatment lines, and dosing frequencies. Additionally, it provides information about companies involved in the development of myeloid cell-targeting therapeutics, including their establishment year, company size, and headquarters location.
  • Comprehensive profiles of key players engaged in myeloid cell-targeting therapeutics development. Each profile includes a brief company overview, details about their drug candidates, available financial information (if applicable), recent developments, and an informed future outlook.
  • In-depth analysis of completed and ongoing clinical trials related to myeloid cell-targeting therapeutics. The analysis considers trial status, registration year, sponsor/collaborator type, study design, and enrolled patient numbers. Additionally, the chapter highlights trends over the years in completed and ongoing trials, patient age groups, participation of industry and non-industry players, and trial locations.
  • A thorough review of over 10,000 peer-reviewed scientific articles related to myeloid cell-targeting therapeutics research. Analysis includes parameters such as publication year, emerging research focus, publication type, therapeutic area, and target indication. The chapter also identifies leading journals and authors (based on the number of articles published).
  • Detailed examination of academic grants awarded to various research institutes for myeloid cell-targeting therapeutics projects from 2017 to 2021. Parameters considered include grant award year, funding amount, funding institute center type, notable NIH departments, support duration, emerging research areas, grant purposes, grant activity codes, local grant recipients, recipient organization study sections, and grant application types. Additionally, the chapter highlights top recipient organizations based on the number of grants and total funding received, along with prominent program officers.
  • Analysis of partnerships established within the myeloid cell-targeting therapeutics market since 2017, encompassing research and development agreements, clinical trial agreements, mergers/acquisitions, product development and commercialization agreements, licensing agreements, asset acquisitions, and product development/manufacturing agreements.
  • A comprehensive analysis of investments made in companies focused on myeloid cell-targeting therapeutics since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offerings, other equity investments, post-IPO equity investments, and equity crowdfunding.
  • An examination of start-ups/small companies engaged in the development of myeloid cell-targeting therapeutics, considering pipeline strength, pipeline maturity, indication diversity, financial backing, number of investors, partnership activity, and start-up health indexing.
  • A case study on companies developing macrophage-based therapeutics, including analyses of development phase, molecule type, target indications, therapeutic areas, establishment year, company size, and headquarters location of the involved companies.


Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the myeloid cell targeting therapeutics market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
  • You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.


Key Market Companies

  • ChemoCentryx
  • Daiichi Sankyo
  • Gilead Sciences
  • Janssen Biotech
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Macrophage Pharma
  • Enlivex, Immune-Onc Therapeutics
  • Infinity Pharmaceuticals
  • AstraZeneca